A week ago, researchers at the University of Florida published a study in Nature Metabolism suggesting that glucosamine — the joint supplement taken by tens of millions of older Americans — may accelerate the progression of Alzheimer's disease by 25 percent. The finding prompted alarm, and appropriately so. But it also provides an important moment to step back and survey a landscape that has changed profoundly since 2023: Alzheimer's disease is no longer untreatable, and for the first time in history, Americans can be tested for the biological changes of Alzheimer's before symptoms appear and treated with disease-modifying therapies before irreversible damage accumulates.
This is the story of where Alzheimer's medicine stands in June 2026 — grounded in the most current approved therapies, the FDA-cleared blood test now available in clinics, and the lifestyle interventions backed by the strongest evidence.
